Qian J, et al. - In this retrospective analysis of completely lobectomized stage I patients with lung adenocarcinoma (LAD), researchers explored adjuvant chemotherapy (ACT) candidates based on a recurrence risk-scoring model. This study included a non-ACT group comprising 3514 patients and an ACT group with 1092 patients. They used Cox proportional hazards regression and developed nomogram predicting recurrence-free survival (RFS) in the non-ACT group. Among the overall study sample, the nomogram-based risk score was calculated. Age, sex, tumor size, pathological subtype, visceral pleural invasion, and lymphovascular invasion were the independent predictors that showed relation to RFS. A more accurate RFS prediction was done using the nomogram vs the 8th TNM staging. In this study, an individual prediction of RFS for stage I LAD post-lobectomy was enabled by nomogram. Postoperative ACT could be beneficial in high-risk patients (score ≥ 245).